X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Advance price notification: A transparency measure that fails patients

By Saumil Pandya and Emily Donaldson  |    March 29, 2018
Most transparency reforms aim to correct perceived misaligned incentives in the biopharmaceutical marketplace. However, many efforts to mandate information flow in the private market have serious...   Read More

340B Spotlight: How much money are hospitals pocketing under 340B and what are they doing with those profits?

By Nicole Longo  |    March 28, 2018
The once little-known 340B drug discount program, which was designed to help low-income, uninsured or otherwise vulnerable patients access prescription medicines at safety-net facilities, is now a...   Read More

New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed

By Holly Campbell  |    March 27, 2018
Today, as part of the Let’s Talk About Cost campaign, PhRMA unveiled new advertisements highlighting how the use of copay accumulator programs by insurance companies and other middlemen could...   Read More

Medicare Monday: Moran finds Part B medicine prices are stable, not a key driver of Medicare costs

By Nicole Longo  |    March 26, 2018
Earlier this year, we examined research that shows Part B spending continues to be a small, stable share of overall Medicare spending. Today, we’re looking at the trends in Average Sales Price...   Read More

Improving care quality by engaging patients in shared decision making

By Randy Burkholder  |    March 22, 2018
With the rapid movement towards value-based payment and delivery in health care, it is critical not to leave one of the key players behind: the patient.     Read More

Video: How does the supply chain shape brand-name medicine prices?

By Holly Campbell  |    March 19, 2018
A medicine’s path from the biopharmaceutical company to the patient is complex and involves many entities across the biopharmaceutical supply chain. In fact, more than one-third of the initial...   Read More

What is inter partes review and why does it matter?

By Nicole Longo  |    March 16, 2018
For more than three decades Hatch-Waxman (the Drug Price Competition and Patent Term Restoration Act of 1984) has encouraged innovation in biopharmaceutical development while at the same time...   Read More

ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access

By Joe Vandigo  |    March 15, 2018
To address rising health care costs and help patients better access new medicines, biopharmaceutical companies are sharing financial risk with payers through new payment arrangements, like...   Read More

4 Things to know about the IQVIA 2018 and Beyond: Outlook and Turning Points report

By Holly Campbell  |    March 13, 2018
We continue to see a deluge of data from government actuaries and pharmacy benefit managers (PBMs) showing a dramatic slowdown in medicine spending growth. Most recently, the IQVIA Institute for...   Read More

Ask About Adherence: New study demonstrates how adherence programs can improve health outcomes for patients with cardiovascular disease

By Carolyn Ha  |    March 7, 2018
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we feature a recent study on medication synchronization programs.   Read More

ICYMI – Survey underscores daily burden of migraines

By Emma Van Hook  |    March 5, 2018
A new survey reveals the painful and disruptive reality of migraine for many patients, with many patients living with pain for nearly half of every month. The survey paints a picture of the...   Read More

ICYMI – Two PBM reports show dramatic slowdown in medicine spending growth

By Holly Campbell  |    March 2, 2018
Newly released pharmacy benefit manager (PBM) data show medicine spending is growing at the slowest rate in years. After accounting for discounts and rebates negotiated with biopharmaceutical...   Read More

New Report: America's biopharmaceutical industry supports 4.7 million jobs

By Nick McGee  |    March 1, 2018
Every day, America’s biopharmaceutical sector supports the jobs of 4.7 million men and women across the country while working to discover and deliver new treatments and cures for patients across...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates